Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

已取消 10 由 L+7 发布于 2026/11/2 17:18:10

DOI:10.1016/S2213-2600(22)00309-5
作者：Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildiko Horva
文献类型：期刊论文
补充材料：只需要正文
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。

Elsevier

Abstract：Background: Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/m2 every 3 weeks) re

应助信息

2026-11-02

Book学术机器人

2026/11/2 17:18:10 未找到该文献，机器人已退出，请等待人工下载

2026/11/2 17:18:10 Book学术AI机器人收到请求，开始寻找文献

2026/11/2 17:18:10 已向机器人发送请求

2026-11-02

L+7 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierAccelerating hydrogen evolution catalyst discovery via data-driven strategy for high-performance single-atom catalysts embedded in h-BN